drugset
drugset / Trial / NCT04965337

Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects

NCT04965337 ↗

Phase 1 Completed 30 enrolled Ascletis Pharmaceuticals Co., Ltd.
RandomizedParallel-groupTriple-blindOther

Summary

This is a Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, Single Center Bridging Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects.

Timeline

Start
2021-07-11
Primary completion
2021-08-01
Completion
2021-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ASC42 Unknown — Oral

Indications

No indication recorded.